Growth Hormone for Cystic Fibrosis-Related Wasting

This study focuses on using Growth Hormone (GH) therapy to address wasting, which is severe weight loss, in adults who have Cystic Fibrosis (CF). Wasting can greatly impact the quality of life and overall health of individuals with CF. By exploring how GH therapy affects weight, quality of life, and diabetes management in these patients, the study aims to improve treatment strategies for CF-related complications. This research is important because it could lead to better ways to help CF patients maintain a healthier weight, improve their quality of life, and manage diabetes, which are significant challenges in their care. Participants in this study will receive Growth Hormone therapy and will have their progress monitored in several ways. Their weight changes will be tracked to see if there is any improvement from the baseline. Additionally, body composition will be assessed using bioelectrical impedance analysis to measure changes in fat-free mass. Quality of life will be evaluated using CF-specific questionnaires, and adherence to the therapy will be monitored through patient reports. The study will also examine the therapy's impact on diabetes, looking at insulin sensitivity and glycemic control. Changes in lung function, muscle strength, and certain serum markers will also be evaluated to understand the broader effects of the therapy. The study is in its early phase, which means it is primarily focused on understanding the treatment's effects and safety.